ASCO publishes guideline on treating pregnant women with blood cancers

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans.

May 01, 2026

Vol.52 No.17

By Claire Marie Porter

In Brief

Neal Meropol named PI of ASCO’s TAPUR study

Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Results from the phase I/II multicenter international CADENZA trial, led by researchers at the University of Texas MD Anderson Cancer Center, show that 75% of patients with blastic plasmacytoid dendritic cell neoplasm who were treated with the antibody-drug conjugate pivekimab sunirine had a complete response.

February 20, 2026

Vol.52 No.07

In Brief

University of York awarded £2.5 million to study blood cancers in the U.K.

Researchers at the University of York have received a £2.5 million boost from Cancer Research U.K., helping to transform future care for people diagnosed with blood cancers.

February 06, 2026

Vol.52 No.05

ASCO publishes guideline on treating pregnant women with blood cancers

YOU MAY BE INTERESTED IN

Collaborative work behind the scenes makes cancer breakthroughs possible

By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

University of York awarded £2.5 million to study blood cancers in the U.K.

Renew today!

Subscriber content

Never miss an issue!

Login

ASCO publishes guideline on treating pregnant women with blood cancers

YOU MAY BE INTERESTED IN

Collaborative work behind the scenes makes cancer breakthroughs possible

By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panelRansohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

University of York awarded £2.5 million to study blood cancers in the U.K.

Never miss an issue!

Login

By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”